Targeting a key protein interaction to fight cancer
Therapeutic targeting of MYC interactions with an essential cofactor
['FUNDING_R21'] · DARTMOUTH COLLEGE · NIH-10655655
This study is looking for new medicines that can help fight certain cancers, especially triple negative breast cancer, by blocking a protein called MYC that often works too much, and they’re testing these potential treatments in lab models to see how well they can slow down cancer growth.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DARTMOUTH COLLEGE (nih funded) |
| Locations | 1 site (HANOVER, UNITED STATES) |
| Trial ID | NIH-10655655 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new drugs that inhibit the function of the MYC protein, which is commonly overactive in many cancers. The team is using a specialized assay to identify small molecules that can block the interaction between MYC and its essential cofactor, TRRAP. By testing these compounds in cancer cell models, particularly in triple negative breast cancer, they aim to determine their effectiveness in reducing cancer cell growth. The ultimate goal is to advance the most promising compounds towards preclinical testing.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers characterized by high levels of MYC expression, such as triple negative breast cancer.
Not a fit: Patients whose cancers do not involve MYC overexpression or those with non-malignant conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with various types of cancer, particularly those with high MYC activity.
How similar studies have performed: Previous research has shown promise in targeting MYC-related pathways, indicating that this approach could be a viable strategy for cancer treatment.
Where this research is happening
HANOVER, UNITED STATES
- DARTMOUTH COLLEGE — HANOVER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COLE, MICHAEL DAVID — DARTMOUTH COLLEGE
- Study coordinator: COLE, MICHAEL DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer